Pulmonary sarcomatoid_MEDI4736+Treme
- Sponsor
- Seoul National University Hospital
- Study ID
- NCT03022500
- Phase
- PHASE2
- Status
- Completed
Conditions
- Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- durvalumab + tremelimumab — DRUGDurvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study Details
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Key Dates
- Start date
- May 18, 2017
- Status verified
- May 2024
- Primary completion
- Feb 28, 2018
- Completion
- Nov 30, 2019
Study Design
- Enrollment
- 32 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: durvalumab + tremelimumabDurvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Primary Outcome Measure
Response rate (RR) [ Time Frame: 12 months after the first date of treatment ]